TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial 讲者:Maria Vittoria Dieci (Padova, Italy) 简短口头报告专场1——转移性乳腺癌 Mini oral session1- Breast cancer, metasta...
2024年欧洲肿瘤内科学会(ESMO)年会已经圆满落幕,在为期5天的学术盛宴中,大会披露了众多乳腺癌领域的前沿进展和重磅研究结果。其中,聚焦HER2阳性乳腺癌脑转移(BM)治疗难题的DESTINY-Breast12(DB-12)研究在会议首日惊艳登场,且研究结果...
Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
From pivotal Phase III trials to novel therapeutic approaches, the ESMO 2024 conference will showcase groundbreaking data across various settings, including early and advanced/metastatic breast cancer.
[6]Kalinsky K, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. ASCO 2024. Abstract # LBA1001. ...
图2. VET对HR阳性乳腺癌患者和接受芳香化酶抑制剂治疗的患者的无病生存期有不利影响(2024ESMO BC, Abstract 268MO) 体育锻炼等非药物干预措施是一种有价值的选择,可抵消女性在癌症治疗期间和结束后身体健康和健康相关生活质量的下降(Breast Cancer. 2022;29:402-418)。同样在2024 ESMO BC大会上报告的一项随机研...
of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr RF01-01....
6.Visani L, Ratosa I, Linderholm BK, et al. Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study. 2024 ESMO Abstract 379P....
在当地时间9月15日的转移性乳腺癌简短口头报告专场1中,复旦大学附属肿瘤医院胡夕春教授就“Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results fro...
2024年,ESMO转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将戈沙妥珠单抗(SG)治疗转移性三阴性乳腺癌(mTNBC)的ESMO临床获益量表(ESMO-MCBS)评分,由既往的4分调整为最高等级5分[1-2];目前,SG是mTNBC二线治疗唯一的首选推荐(I类证据,推荐等级A)。